▲ +149.08% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Corvus Pharmaceuticals in the last 3 months. The average price target is $6.75, with a high forecast of $9.50 and a low forecast of $4.00. The average price target represents a 149.08% upside from the last price of $2.71.
The current consensus among 2 polled investment analysts is to buy stock in Corvus Pharmaceuticals. This Buy consensus rating has held steady for over two years.
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase Ib/2 clinical trial for adenosine, an immune checkpoint. The company is also developing CPI-006, an anti-CD73 monoclonal antibody, which is in Phase I/Ib clinical trial that inhibits the production of adenosine and stimulate various immune cells, as well as Phase I clinical trial of CPI-006 for COVID-19; an antagonist of the adenosine A2B receptor; and CPI-818, a small molecule covalent inhibitor of interleukin-2-inducible T-cell kinase, that is Phase I/Ib clinical trial. Corvus Pharmaceuticals, Inc. also entered into a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was founded in 2014 and is based in Burlingame, California.